Retatrutide: the triple agonist - current evidence and what's still missing

TL;DR

• Retatrutide is a triple agonist - GLP-1 + GIP + glucagon, the third arm adding energy expenditure and liver-fat mobilisation.
• TRIUMPH-1 reported 28.3% mean weight reduction at the top dose arm versus 2.2% on placebo under the efficacy estimand, and 25.0% versus 3.9% under the more conservative treatment-regimen estimand; the 30.3% often quoted is a separate 104-week extension in 532 participants with a BMI of 35 or more.
• TRIUMPH-2 (1,152 adults with type 2 diabetes) reached 12.7%, 19.1% and 20.8% across its three dose arms (versus 4.0% on placebo), and TRIUMPH-3 (1,949 adults with heart disease) 21.6% and 22.6% in its two higher-dose arms (versus 3.2%), both efficacy-estimand figures announced 23 July 2026 and both against placebo only; TRIUMPH-4 reached 28.7% at 68 weeks - so the honest summary is a range across trials, not one figure.
• The head-to-head against tirzepatide has not reported - TRIUMPH-5 is closed to new participants, primary completion is expected around December 2026, and readout is 2027 or later. TRIUMPH-6 has not reported either.
• Cardiovascular and kidney outcomes are still a blank - TRIUMPH-Outcomes, at roughly 10,000 participants, has not reported.
• Investigational and unapproved for any indication - the BLA is planned for Q1 2027, the biologic-versus-drug pathway is in unresolved litigation with the FDA, and there is no legitimate access.

Updated October 2026 (26 Oct): re-verified against Lilly's 23 July 2026 release. Adds TRIUMPH-2's full dose-arm range (12.7% / 19.1% / 20.8%), participant count and placebo HbA1c figure, TRIUMPH-3's second higher-dose arm (21.6%), and states that every TRIUMPH readout so far is placebo-controlled. Status markers moved to 26 October 2026; the BLA is still planned, not filed. Replaces a supply-verification CTA with a plain status link and a bloodwork-first recommendation.

Updated October 2026: corrects the TRIUMPH-1 estimand labels against Lilly's release: 28.3% is the efficacy estimand, 25.0% (versus 3.9% placebo) is the treatment-regimen estimand, and 30.3% is the 104-week extension in 532 participants with BMI of 35 or more; adds placebo figures for TRIUMPH-2 and TRIUMPH-3.

Updated September 2026: separates the TRIUMPH figures that this page had been carrying as a blended range (TRIUMPH-2 at 20.8% with up to 1.6 percentage points of HbA1c reduction, TRIUMPH-3 at 22.6% in 1,949 participants with established cardiovascular disease, TRIUMPH-4 at 28.7% at 68 weeks) and replaces the "~30% in a 104-week extension" reading of TRIUMPH-1 with what the estimands actually are: 28.3% under the treatment-regimen estimand, up to 30.3% under the efficacy estimand. Adds TRIUMPH-6 to the map as unreported.

Updated September 2026: routes the closing call-to-action to a consult rather than a compound page, which is the right destination for a compound that is investigational and not available.

Updated September 2026 (3): TRIUMPH-5 status re-verified 14 September 2026 - still active, not recruiting, still unreported, earliest readout 2027 or later. The TRIUMPH map and references carried an "as of August 2026" status marker while the body read September; both now read September 2026.

Updated September 2026 (2): carries the TRIUMPH-5 December 2026 primary-completion date into the body, trial table, summary table and FAQ rather than leaving it in this changelog, with the collection-versus-readout distinction stated where readers meet the date.

Updated September 2026: re-verified as of 3 September 2026: TRIUMPH-5 still has not reported. Notes that its expected primary completion (~December 2026) is a data-collection milestone, not a result; earliest readout remains 2027 or later. Retatrutide remains investigational and not FDA-approved.

Updated August 2026: confirms the TRIUMPH-2 and TRIUMPH-3 toplines (both met their primary endpoints at 80 weeks), adds the Q1 2027 BLA plan and the reason for its delay, adds the unresolved FDA dispute over whether retatrutide is regulated as a biologic or a drug, and keeps the correction that TRIUMPH-5 - the first randomised head-to-head against tirzepatide - has not read out and is not expected before 2027.

---

Retatrutide (investigational) is the most-hyped drug in obesity medicine right now, and for a real reason: it's a triple agonist (GLP-1 + GIP + glucagon) that, in its first Phase 3 trial, produced a mean 28.3% body weight reduction in the top dose arm over 80 weeks under the efficacy estimand - the highest figure the class has posted. But hype outruns evidence, so this is the honest ledger: what the trials actually show, and the substantial list of what's still missing before retatrutide is a real-world option. The short version: genuinely exciting data, genuinely incomplete picture, and not something you can get yet.

Looking for the full picture? This page covers the retatrutide evidence base specifically. For how the whole class fits together - single, dual and triple agonists plus the amylin branch, with the 2026 trial data - start with GLP-1 generations compared.

2026 regulatory status - re-verified 26 October 2026. An earlier version of this page said "all four core TRIUMPH trials have now reported." That was wrong, and it understated the size of the programme. TRIUMPH is larger than four trials, and two of the most consequential - TRIUMPH-5, the head-to-head against tirzepatide, and TRIUMPH-Outcomes, the cardiovascular and kidney outcomes trial - have not reported. What has now been confirmed is the middle of the programme: TRIUMPH-2 and TRIUMPH-3 toplines were announced together on 23 July 2026, and both met their primary endpoints - up to 20.8% in 1,152 adults with obesity and type 2 diabetes and up to 22.6% at 80 weeks in 1,949 participants with established cardiovascular disease, each against placebo. TRIUMPH-6 has not reported. Lilly plans to submit a Biologics License Application to the FDA in Q1 2027; as of 26 October 2026 it has not been submitted, and the regulatory pathway itself is the subject of an unresolved legal dispute with the FDA (below). A planned submission is not an approval: retatrutide (investigational) is not approved in any market for any indication, and the FDA has stated it is not a component of an approved drug and cannot legally be used in compounding.

The single most important thing on this page

There is still no head-to-head result for retatrutide (investigational) against tirzepatide.

The trial that will produce one - TRIUMPH-5 (NCT06662383) - is the first randomised head-to-head of the two drugs. As of September 2026 it is active, not recruiting: it is closed to new participants, and its expected primary completion is around December 2026. That date deserves care, because it will be misreported. Primary completion is when the trial finishes collecting the data for its main endpoint - not when anyone learns the answer. Database lock, analysis, write-up and presentation all follow it, so the earliest readouts remain 2027 or later. It has not reported. Anyone quoting a "retatrutide beat tirzepatide" figure in 2026 is not quoting TRIUMPH-5, because TRIUMPH-5 has produced no figure to quote.

And this is the correction that matters most: you cannot subtract percentages across separate trials. Retatrutide's obesity-trial weight loss of roughly 28–29% and tirzepatide's roughly 21–23% come from different trials, with different populations, different entry criteria, different durations and different designs. Putting them side by side and taking the difference produces a number that describes nothing real. It is not a margin, it is an artefact of comparing two things that were never measured against each other. The honest statement is: retatrutide's separate-trial numbers are higher, and whether it is actually superior in a like-for-like comparison is an open question that TRIUMPH-5 exists to answer and has not yet answered.

The TRIUMPH map - what has reported and what hasn't

Two notes on reading that table honestly. First, the two trials that would answer the questions people most want answered - is it better than tirzepatide, and does it prevent heart attacks, strokes and kidney decline - are precisely the two that have not reported. Weight loss is a surrogate; outcomes are the endpoint that changes practice. Second, note what TRIUMPH-2 and TRIUMPH-3 do and don't add. They are genuine wins: two 80-week Phase 3 trials, reported together on 23 July 2026, that met their primary endpoints - which is what a programme heading for a regulatory submission needs. But 20.8% and 22.6% sit below TRIUMPH-1's 28.3%, which is a useful reminder that a single flagship number is not the whole programme - different trials, different populations, different results, and the honest summary of retatrutide's (investigational) efficacy is a range across trials, not one figure.

Why TRIUMPH-1 has three numbers in circulation

TRIUMPH-1's top dose arm is quoted as 28.3%, 25.0% and 30.3%, and each means something different. 28.3% (versus 2.2% on placebo) is the efficacy estimand: the estimated effect had all randomised participants stayed on the study drug; it answers "what does the drug do when taken." 25.0% (versus 3.9% on placebo) is the treatment-regimen estimand: the average effect regardless of adherence, counting people who stopped the drug; it answers "what happens to a population offered this treatment," and is the more conservative figure. Both describe the same 80-week result. 30.3% is not an estimand of that result at all: it comes from a pre-specified 104-week extension in 532 participants with a baseline BMI of 35 or more who completed the main study. Anyone quoting 30.3% as the TRIUMPH-1 result is quoting a subgroup over a longer period, and anyone quoting 28.3% should know it is the efficacy estimand.

The regulatory picture: a Q1 2027 filing, and a fight about what kind of drug this is

Two things are worth separating here, because they're usually blurred together.

The filing. Lilly plans to submit a Biologics License Application in Q1 2027. That is later than the end-2026 timeline previously expected, and the stated reason is unglamorous and reassuring rather than alarming: more manufacturing and quality-control data was needed. That is a chemistry-and-manufacturing question, not an efficacy or safety signal - but it is a real delay, and anyone who told you retatrutide (investigational) would be filed in 2026 was working from the old expectation. The initial indications being sought are obesity, obstructive sleep apnoea, and knee osteoarthritis pain - which tracks the shape of the trial programme, TRIUMPH-4 included.

The fight nobody covers. There is an unresolved legal dispute between Lilly and the FDA over the regulatory pathway itself - specifically, whether retatrutide is properly regulated as a biologic (a Biologics License Application, carrying 12 years of reference-product exclusivity) or as a drug (a New Drug Application, carrying 5 years). An initial court ruling was mixed, and the litigation continues.

Why this deserves more attention than it gets: the classification question is not a technicality. It determines the exclusivity clock, which determines when generic or biosimilar competition can arrive, which eventually determines what this costs patients. It also sits inside a broader question the field has been circling for years about where the line between "peptide drug" and "biologic" actually falls - a line that has consequences well beyond this one molecule. None of it changes the clinical picture today: retatrutide (investigational) remains unapproved for any indication regardless of which pathway wins. But it is the most consequential open question about this drug that has nothing to do with weight loss, and it is genuinely unresolved.

Separately from TRIUMPH, Lilly runs the TRANSCEND programme, which covers retatrutide (investigational) in type 2 diabetes rather than obesity. It is a different question with different endpoints, it is not a head-to-head against tirzepatide either, and it does not change the approval position: retatrutide remains investigational and unapproved for any indication.

What we know

The genuinely novel part is the glucagon arm. GLP-1 and GIP work largely on appetite and insulin; adding glucagon-receptor activation appears to raise energy expenditure and mobilise liver fat, which is the leading explanation for why retatrutide's (investigational) numbers run higher than the dual agonists'. (More on the mechanism progression in how GLP-1 agonists work.)

What's still missing

This is the part the headlines skip, and it's a long list:

• No head-to-head vs tirzepatide - none, yet. Retatrutide's (investigational) ~28–29% and tirzepatide's ~21–23% come from different trials - different patients, durations, protocols. They cannot be ranked directly, and the difference between them cannot be calculated (the cross-trial trap). TRIUMPH-5 is the trial designed to settle it; it is closed to enrolment, multi-year, and not expected to read out before 2027 at the earliest. Until then, "we genuinely don't know" is the complete answer.
• No cardiovascular or kidney outcomes data. TRIUMPH-Outcomes (~10,000 participants) has not reported. For a class whose approved members are increasingly judged on outcomes rather than scale weight, that is a significant blank.
• Full long-term safety. The glucagon mechanism is the least-trodden of the three; longer, larger safety data across diverse populations is still accumulating.
• Durability and maintenance. Like the rest of the class, the open question is what happens on stopping, and what maintenance looks like - not yet characterised for retatrutide (investigational).
• Approval and access. It's not approved for any indication and not yet filed - the BLA is planned for Q1 2027, pushed back from an earlier end-2026 expectation because more manufacturing and quality-control data was needed, and with the pathway itself under dispute. Filing opens a review rather than concluding one, so on a realistic reading an approval, if it comes, sits in late 2027 to 2028 at the earliest. So there's no legitimate way to obtain it - and the grey-market "research retatrutide" that appears whenever results trend carries every contamination and counterfeit risk, with even less known about safe handling. In August 2026 a research-peptide seller was sentenced to 70 months in federal prison after admitting he forged certificates of analysis for his products; that is the standard of documentation the grey market actually operates to.
• Real-world tolerability. As the most potent, its dose-related GI effects in real-world (non-trial) use are still to be seen.

How to think about it today

The mature posture: retatrutide (investigational) is the most promising thing on the horizon and an unfinished story. It may well reset the ceiling for weight loss - but "may," "horizon," and "investigational" are the operative words, and the comparison everyone is already making in their heads is a trial that has not run its course. For anyone making decisions now, it's a reason to work with a clinician who tracks the pipeline, not a reason to wait on the sidelines for a drug you can't get while an approved, available option sits in front of you. The smart move is to start with what's proven and fold retatrutide in if and when it's actually approved.

The bottom line - and where to start

Retatrutide's Phase 3 numbers are real and remarkable - 28.3% in TRIUMPH-1 under the efficacy estimand, and 25.0% under the more conservative treatment-regimen estimand, is unprecedented for a drug, and TRIUMPH-2 and TRIUMPH-3 have now both met their primary endpoints at 80 weeks, at 20.8% and 22.6% respectively. But the picture is incomplete: the head-to-head against tirzepatide has not reported and is not expected before 2027, TRIUMPH-6 has not reported, the cardiovascular and kidney outcomes trial has not reported, long-term safety is maturing, durability is unknown, the filing itself has slipped to Q1 2027 with the regulatory pathway still being fought over in court, and there is no legitimate access. Don't treat it as available, and don't treat cross-trial arithmetic as proof it is best. Take it seriously as the likely next leap: the trials that will answer the open questions are running, and approved options exist today.

Where Vivre Labs fits

Vivre Labs keeps a retatrutide page that sets out where it stands: investigational, not approved for any indication, with a US filing planned for Q1 2027. Whatever you are weighing up, we recommend starting with baseline bloodwork, so you and your own doctor are working from measured numbers.

Frequently asked questions

How much weight does retatrutide cause you to lose? In its first Phase 3 trial (TRIUMPH-1), 28.3% on average in the top dose arm over 80 weeks versus 2.2% on placebo under the efficacy estimand, and 25.0% versus 3.9% under the treatment-regimen estimand, which counts everyone regardless of adherence and is the more conservative figure. The 30.3% sometimes quoted is from a separate 104-week extension in 532 participants with a BMI of 35 or more. TRIUMPH-2 and TRIUMPH-3, also 80 weeks, reported up to 20.8% and 22.6% in their highest-dose arms (versus 4.0% and 3.2% on placebo), and TRIUMPH-4 reported 28.7% at 68 weeks. So the honest answer is a range across trials, not one number. Retatrutide is investigational; those are trial figures for study populations, not a result you can obtain.

Is retatrutide better than tirzepatide? Unknown. On separate trial numbers retatrutide (investigational) produced more weight loss - roughly 28–29% in its obesity trials against tirzepatide's roughly 21–23% - but those figures come from different trials with different populations and designs, and subtracting one from the other produces a meaningless number. The first randomised head-to-head, TRIUMPH-5, is closed to enrolment, multi-year, and has not reported; readouts are not expected before 2027. "Higher on paper, untested against tirzepatide" remains the honest answer.

Have TRIUMPH-2 and TRIUMPH-3 reported? Yes - their toplines were announced together on 23 July 2026, and both met their primary endpoints. TRIUMPH-2, in 1,152 adults with obesity and type 2 diabetes, reported 12.7%, 19.1% and 20.8% weight reduction across its three dose arms (versus 4.0% on placebo), with HbA1c down 1.4 to 1.6 points (versus 0.2 on placebo). TRIUMPH-3, in 1,949 participants with established cardiovascular disease, reported 21.6% and 22.6% in its two higher-dose arms at 80 weeks (versus 3.2% on placebo) with improvements in triglycerides, blood pressure and inflammatory markers. Both sit below TRIUMPH-1's 28.3%, which is a useful corrective: the programme produces a range, not a single number. Retatrutide remains investigational.

Have TRIUMPH-5 and TRIUMPH-6 reported? No - neither has. TRIUMPH-5 is the head-to-head against tirzepatide and TRIUMPH-6 has produced no topline either. Any claim resting on a result from either trial is describing something that does not exist yet.

When will retatrutide be approved? There's no approval date, because there isn't yet an application (none had been submitted as of 26 October 2026). Lilly plans to submit a Biologics License Application in Q1 2027, delayed from an earlier end-2026 expectation because more manufacturing and quality-control data was required. The indications initially sought are obesity, obstructive sleep apnoea, and knee osteoarthritis pain. A planned filing is not an approval, and review takes further time after submission - on a realistic reading, an approval would sit in late 2027 to 2028 at the earliest. Note also that this is a Biologics License Application, not a New Drug Application: retatrutide is being handled on the biologics pathway, and anyone describing an "NDA in 2026" is working from an expectation that has been superseded.

What is the FDA dispute about? Whether retatrutide (investigational) is properly regulated as a biologic - via a Biologics License Application, with 12 years of reference-product exclusivity - or as a drug, via a New Drug Application, with 5 years. An initial court ruling was mixed and the litigation continues. It affects the exclusivity clock and therefore how soon competition and lower prices can arrive; it does not change the fact that the drug is unapproved today.

Has TRIUMPH-5 reported? No. TRIUMPH-5 (NCT06662383) is the first randomised head-to-head of retatrutide (investigational) versus tirzepatide. As of October 2026 it is active but not recruiting - closed to new participants. Its expected primary completion is around December 2026, but that is a data-collection milestone rather than a result; the earliest readouts are 2027 or later. Any claim about how the two compare head-to-head is, today, an extrapolation and not a result.

Is retatrutide available yet? No. It's investigational - not approved for any indication, and not available through legitimate channels. Grey-market "retatrutide" carries serious risks and should be avoided.

What makes retatrutide different? It adds a third pathway, glucagon, to GLP-1 and GIP - which appears to raise energy expenditure and mobilise liver fat, the likely reason for its larger weight-loss numbers. It remains investigational.

Related reading

• Tirzepatide vs retatrutide · The four compounds compared · How GLP-1 agonists work · Retatrutide's third receptor
• Part of The Complete Guide to GLP-1s

---

Educational content, not medical advice. Retatrutide is investigational, not approved for any indication, and not available through legitimate channels; cross-trial comparisons are not head-to-head evidence and percentages from separate trials cannot be subtracted from one another. Trial figures describe study populations. Claims for the Malaysian market are subject to MAB requirements.

References

• Eli Lilly. TRIUMPH-1 Phase 3 topline (retatrutide), 21 May 2026, n=2,339 - all three dose arms met the primary and key secondary endpoints; top dose arm 28.3% mean weight reduction versus 2.2% placebo under the efficacy estimand, 25.0% versus 3.9% placebo under the treatment-regimen estimand, 45.3% of that arm reaching ≥30% reduction; 30.3% in a pre-specified 104-week extension in 532 participants with baseline BMI ≥35. · Eli Lilly investor release, 23 July 2026, "Lilly's triple agonist retatrutide successful in two additional Phase 3 obesity trials" (investor.lilly.com; also HCPLive, 23 July 2026): both met their primary endpoints; placebo-controlled. TRIUMPH-2 (n=1,152, obesity/overweight with type 2 diabetes, 80 weeks): 12.7% / 19.1% / 20.8% across ascending dose arms versus 4.0% placebo; HbA1c 1.4 to 1.6 points versus 0.2 placebo from a 7.7% baseline. TRIUMPH-3 (n=1,949, BMI 35+ with established cardiovascular disease, 80 weeks): 21.6% and 22.6% in the two higher-dose arms versus 3.2% placebo (efficacy estimand), with improvements in triglycerides, blood pressure and inflammatory markers. CMC package in completion; US BLA submission planned Q1 2027. · TRIUMPH-4 (knee OA), 11 Dec 2025 - 28.7% at 68 weeks, with improvement in pain and physical function. · TRIUMPH-5, NCT06662383 - first randomised head-to-head of retatrutide vs tirzepatide; status re-checked 26 October 2026: active, not recruiting (closed to new participants); multi-year, earliest readouts 2027 or later; has not reported. · TRIUMPH-6 - has not reported; no topline announced as of 26 October 2026. · TRIUMPH-Outcomes, NCT06383390 - cardiovascular/kidney outcomes trial, approximately 10,000 participants; multi-year; has not reported. · TRANSCEND programme - retatrutide in type 2 diabetes; separate from the TRIUMPH obesity programme. · Retatrutide remains investigational and is not FDA-approved for any indication; FDA has stated it is not a component of an approved drug and cannot lawfully be used in compounding. · Cross-trial comparison caveat: retatrutide obesity-trial weight loss of roughly 28–29% and tirzepatide's roughly 21–23% derive from separate trials with different populations and designs and are not a valid basis for calculating a difference. · Jastreboff AM, et al. Retatrutide phase 2. N Engl J Med. 2023;389:514–526. · US Department of Justice (USAO-NDIN), 3 August 2026 - sentencing of a research-peptide seller who admitted forging certificates of analysis. · Eli Lilly - planned Biologics License Application in Q1 2027, delayed from an earlier end-2026 expectation pending additional manufacturing and quality-control data; initial indications sought: obesity, obstructive sleep apnoea, knee osteoarthritis pain. · Lilly v. FDA - unresolved dispute over whether retatrutide is regulated as a biologic (BLA; 12-year reference-product exclusivity) or a drug (NDA; 5-year); initial ruling mixed, litigation ongoing.